The value of contrast-enhanced computed tomography in predicting gastric cancer recurrence and metastasis

Li, Chunfeng; Zheng, Jian; Xue, Yingwei

doi:10.3233/cbm-160528

Cited by 7 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study published in 2017 demonstrated that the maximum HU value represents the highest degree of tumor enhancement reflecting the more aggressive tumors [28]. In another study that investigated the predictive value of CT at diagnosis for early recurrence and metastasis in GC patients, it was found that compared with patients without recurrence and metastasis, those with recurrence and metastasis demonstrated higher CT values in the arterial and venous phases [29]. Both higher T stage accuracy, predictive, and prognostic importance of CT attenuation in GC patients may be related to increased neovascularization [30].…”

Section: Discussionmentioning

confidence: 99%

Does the Computed Tomography Hounsfield Units Change Predict Response to Perioperative Chemotherapy in Patients with Gastric Adenocarcinoma

Cihan¹,

Önol²,

Erhan³

2022

J. Cancer

View full text Add to dashboard Cite

Purpose:We aimed to investigate whether Computed Tomography (CT) attenuation change is predictive of poor pathological response in patients with gastric cancer (GC) and gastroesophageal junction (GEJ) adenocarcinoma who received perioperative fluorouracil (FU), leucovorin (LV), oxaliplatin, and docetaxel (FLOT) regimen. Methods: This trial was planned as a retrospective single-center study. In the neoadjuvant setting, patients received a regimen that includes docetaxel (50 mg/m 2 ), oxaliplatin (85 mg/m 2 ), and LV (200 mg/m 2 ) with short-term infusional FU (2600 mg/m 2 as a 24-hour infusion), on day 1 and administered every two weeks for four cycles. Patients were classified as response rates according to the CAP-TRG system (0-1 response or 2-3 response) after completing four cycles of the FLOT regimen. Results: In total, 108 patients with GC and GEJ adenocarcinoma were included in the study. In a univariate analysis, age, histologic grade, T stage, N stage, and change in attenuation were found to be the statistically significant factors (p = 0.034, p =0.038, p = 0.001, p =0.029, and p = 0.022, respectively). In a multivariate analysis, T4 tumors and a higher change in attenuation were found to be important factors associated with poor pathologic response (p = 0.027 and p = 0.038, respectively). Conclusion: Our results demonstrate that a higher decrease in CT attenuation and T4 tumors is associated with a poor response to perioperative FLOT chemotherapy in patients with GC and GEJ adenocarcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Does the Computed Tomography Hounsfield Units Change Predict Response to Perioperative Chemotherapy in Patients with Gastric Adenocarcinoma

Cihan¹,

Önol²,

Erhan³

2022

J. Cancer

View full text Add to dashboard Cite

show abstract

“…[5] In addition, contrast-enhanced computed tomography (CT) was the most commonly used imaging method to detect recurrence of gastric cancer, with a sensitivity of only 70%-73%. [6] Therefore, there is an urgent need for highly accurate biomarkers to detect recurrence of gastric cancer in clinical practice so that patients with recurrence can receive timely treatment and ultimately improve their survival. [7,8] Circulating tumor DNA (ctDNA) is a fragment of DNA that is released into the bloodstream when a tumor undergoes necrosis or apoptosis.…”

Section: Introductionmentioning

confidence: 99%

Circulating tumor DNA predicts recurrence and assesses prognosis in operable gastric cancer: A systematic review and meta-analysis

Mi,

Wang,

Han

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: Selecting the appropriate patient for further treatment after surgery for gastric cancer can improve the patient prognosis. Circulating tumor DNA (ctDNA) has the potential to predict recurrence and prognosis after gastric cancer surgery, but the results are still inconclusive. As the completed studies had small sample sizes and were inconsistent, a meta-analysis was conducted to assess the effect of ctDNA on recurrence and prognosis after gastric cancer surgery. Methods: PubMed, Embase, Scopus, and the Web of Science were searched for potentially eligible studies published up to April 7, 2023. Pooled relative risk (RR) and pooled hazard ratio (HR) were calculated to evaluate recurrence, recurrence-free survival (RFS), and overall survival (OS) following gastric cancer surgery. Results: A pooled analysis revealed that patients who were ctDNA positive before and after surgery were at a high risk of gastric cancer recurrence (RR = 1.79, 95% CI: 1.19–2.71; RR = 3.17, 95% CI: 2.36–4.25). The pooled data revealed that ctDNA-positive patients had a poorer RFS and OS (HR = 6.37, 95% CI: 2.70–15.01; HR = 4.58, 95% CI: 1.68–12.49). Conclusions: ctDNA-positive patients were at a high risk of recurrence after gastric cancer surgery and had a poorer prognosis. Hence, ctDNA-positive patients needed close follow-up and further treatment.

show abstract

“…Although the incidence of GC is decreasing by nearly 2% per year worldwide, the overall treatment effect has not fundamentally improved due to population growth [3]. The highly invasive behavior of GCs often leads to recurrence and metastasis, which are the main causes of death in patients [4]. GC-related genes, including oncogenes and tumor suppressor genes, are closely related to the malignant biological behavior of GC [5].…”

Section: Introductionmentioning

confidence: 99%

Up-regulation of Rb by small activating RNA inhibits cell invasion and migration in gastric cancer cells

Peng

Zeng

Kong

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Gastric cancer (GC) is a lethal disease that needs further investigation. Recent studies have reported that small activating RNA (saRNA), involved in a process called RNA activation, plays an important role in the development of cancer. Methods: The expression of retinoblastoma (Rb) was detected in human GC tissues and cell lines. We designed three different saRNAs targeting the Rb gene promoter in GC cell lines. Upregulated Rb expression after transfection of the saRNAs was confirmed by PCR and western blotting. And GC cell proliferation, migration, and invasion were detected using CCK8 assays and Transwell assays. Results: Here, we found that Rb displayed lower expression in GC tissues and cells. saRNA-3 significantly increased the expression of Rb in both SGC-7901 and MKN-28 cells. saRNA-3 significantly inhibited the proliferation of both cell types by day 3 after transfection. There was no significant difference between the negative control saRNA and mock transfection groups. saRNA-3 decreased the tumor volume and weight compared with the mock and dsControl groups. In addition, saRNA-3 transfection decreased the migratory ability of SGC-701 and MKN-28 cells.Conclusions: Overall, Rb is a promising novel prognostic biomarker of GC and, due to its role in metastasis, a novel therapeutic target for the clinical management of invasive and metastatic GC.

show abstract

The value of contrast-enhanced computed tomography in predicting gastric cancer recurrence and metastasis

Abstract: Our study suggests that CECT has a high accuracy rate for predicting postoperative GC recurrence and metastasis.

Cited by 7 publications

References 23 publications

Does the Computed Tomography Hounsfield Units Change Predict Response to Perioperative Chemotherapy in Patients with Gastric Adenocarcinoma

Does the Computed Tomography Hounsfield Units Change Predict Response to Perioperative Chemotherapy in Patients with Gastric Adenocarcinoma

Circulating tumor DNA predicts recurrence and assesses prognosis in operable gastric cancer: A systematic review and meta-analysis

Up-regulation of Rb by small activating RNA inhibits cell invasion and migration in gastric cancer cells

Contact Info

Product

Resources

About